PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification [4] :		(11) International Publication Number:
A61L 27/00, C07K 15/12, 15/20 C08J 3/14, C08L 89/00, 89/06	A1	WO 88/ 06043
		(43) International Publication Date: 25 August 1988 (25.08.88)

(21) International Application Number: PCT/AU87/00038

(22) International Filing Date: 12 February 1987 (12.02.87)

(71) Applicant: THE UNIVERSITY OF MELBOURNE [AU/AU]; Grattan Street, Parkville, VIC 3052 (AU).

(72) Inventors: BATEMAN, John, Francis ; 14 Kalimna Street, Balwyn, VIC 3103 (AU). RAMSHAW, John, Alan, Maurice ; 121 Blyth Street, Brunswick, VIC 3056 (AU). PETERS, David, Edward ; Paynters Road, Wonga Park, VIC 3155 (AU). TULLOCH, Peter, Archibald ; 71 Park Drive, Parkville, VIC 3052 (AU).

(74) Agent: SANDERCOCK, SMITH & BEADLE; 207 Riversdale Road, Hawthorn, VIC 3122 (AU).

(81) Designated States: BR, KR.

Published
With international search report.

(54) Title: PRECIPITATION OF COLLAGEN IN TACTOID FORM

(57) Abstract

Collagen in tactoid form obtained by forming an aqueous solution containing dissolved collagen and a water soluble or miscible polymer adapted to precipitate collagen out of solution in the form of tactoids.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic			SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark	MC	Monaco	US	United States of America
FI	Finland	MG	Madagascar		

PRECIPITATION OF COLLAGEN IN TACTOID FORM

This invention relates to collagen products.

In a particular aspect this invention relates to collagen products made from soluble collagen. A new method by which soluble collagen can be formed into quasi- crystalline structures by precipitation using soluble polymers is described. The use of an aggregate of this quasi- crystalline collagen to form a variety of collagen materials which have improved properties compared with existing collagenous materials is described. Such improved collagen materials have application in various fields including the manufacture, for example, of products for medical use.

Collagen is an extremely common protein in the animal kingdom and therefore many uses for products based upon collagen have developed. Many products use collagen in either its native form (i.e. the triple helical structure pre-existing in an animal or human body), or regenerated into this form, or after denaturation of the collagen, in the form of gelatine. Native collagen is used for various products such as in the production of leather from animal skins, or such as the production of sausage casings in which the collagen is finely divided and reformed into the desired structure.

There are also many uses of collagen and for items made from collagen in medical fields such as in artificial arteries, veins, tendons, corneas, heart valves, skin, or patches or the like which are used as replacement parts for disease or injury affected parts in humans, or in cosmetic applications such as mammary prostheses or injectable collagen, or in collagen sponges, sutures or haemostat materials which may be used during surgery or in the treatment of disease (Chvapil, 1979). Many of these medical products made from collagen are at present unsatisfactory because of an inability to reproduce the native structure, composition or strength which exists in the normal collagenous tissue or because of the immune response

elicited by the presence of immunogenic collagen or components or other material foreign to the body.

In its native form in the body, collagen exists in many types and in the most common of these types, collagen exists as fibrils in which individual collagen molecules are arranged in a staggered overlap structure (Bornstein and Traub, 1979). These fibrils are stabilised and made insoluble by intermolecular crosslinks between the non-helical portions (telopeptides) of adjacent collagen molecules (Bornstein and Traub, 1979). If the collagen from normal, mature tissue is to be made soluble the crosslinks must be broken, for example by digestion with an enzyme such as pepsin.

Soluble collagen can be reconstituted in a variety of ordered aggregate forms. Some are fibrous in form, and fibrils in which the collagen is arranged in its native staggered way can be reformed. The rate of the fibril reforming process is enhanced if collagen with intact telopeptides is used. However, results from the use of injectable soluble collagen have shown that the telopeptides lead to an antigenic response in humans; collagen lacking telopeptides is relatively non antigenic (Linsenmayer, 1982) but can still be made to form fibrils. Materials formed by fibril regeneration are often too hydrated and additional methods such as freezedrying or cell-induced contraction must be used to give a functional product.

Other non-native fibrous aggregates, termed FLS collagen, can be formed in which the collagen molecules are arranged in various staggered arrangements with the orientation of the molecules in both directions.

Quasi-crystalline aggregates can also be formed. These include very small crystallites of collagen, termed SLS collagen, in which the collagen molecules all have the same orientation, but there is no stagger between molecules. These have been of partial use in deducing the native structure of collagen but SLS collagen

has been of little use in the manufacture of larger structures like biomedical products. Also, quasi-crystalline tactoids of collagen can be prepared, using conditions similar to those used for reconstituting fibrils by heat gelation (Leibovich and Weiss, 1970; Lee and Piez, 1983) but the technique of production is more difficult than the technique described here as it does not involve simple precipitation. In these structures the collagen is arranged in a staggered form similar to native fibrils. In the present work the tactoids are produced by a new procedure, precipitation by soluble, neutral polymers. When collagen is precipitated by other procedures, for example salts, alcohols or heat, amorphous precipitates are formed.

DESCRIPTION OF THE INVENTION

During a search for more efficient methods of isolating soluble collagen it was found that the addition of water soluble polymers to a solution of collagen resulted in an efficient precipitation of the collagen from solution and the precipitated collagen was found to be much easier to separate from the liquid phase than with precipitates of collagen formed by the use of salts, alcohol or heat. The polymers had other advantages when compared with these previously used precipitants including that they were non-denaturing and did not require removal prior to chromatography or electrophoresis.

It was an unexpected finding that the collagen had precipitated in the form of small, needle-like, quasi-crystalline tactoids which were visible under the light microscope.

It was a further unexpected discovery that the tactoids could be induced to form into larger assemblages either by allowing the suspension to mature for a period of time or by mechanical action, and that the tactoids or their assemblages could be formed into shapes.

Accordingly, the present invention provides a method of producing a collagen product comprising forming an

aqueous solution containing dissolved collagen and a water soluble or miscible polymer adapted to precipitate the collagen out of solution in the form of tactoids.

The pH of the said solution is preferably 3.5-10 more preferably 5-8 with 7-8 being still more preferred and about 7.5 being most preferred.

The collagen precipitate may be left in the form of a paste or slurry and used in this form or after concentration by any one of the methods gravitational precipitation, filtration, centrifugation or the like. The precipitate may be crosslinked, tanned or stabilised by one or more of chemical, physical or biochemical methods either before or after it has been concentrated. Crosslinking, tanning or stabilisation applied to the precipitate before concentration makes the tactoids resistant to deforming actions such as heating, pressure or biochemical degradation. Crosslinking, tanning or stabilisation applied to the precipitate after concentration causes the structure formed during the concentration process to become more stable.

The so precipitated collagen may also be formed, for example, into a synthetic body part. Such forming into a synthetic body part may be effected by gravitational precipitation, filtration, centifugation, moulding, pressing, shaping or any other way or combination of ways.

Shapes which may be prepared include sheets, tubes, strings and rods.

It has been found particularly desirable to form the so precipitated collagen into sheets for use as synthetic dressings for wounds and into tubes for use as synthetic tubular body parts. The sheets can be formed by centrifugation in a large basket centrifuge or the like or by gravitational precipitation or filtration. Other methods of producing the sheets are also possible. A more compacted sheet is produced by centrifugation in comparison with gravitational precipitation or filtration. Tubes can also be prepared by centrifugation

or by casting, moulding or shaping.

The collagen may be precipitated onto a suitable substrate to form a composite material. Such a substrate, onto which the collagen is precipitated, may have the form of a particular body part or biomedical product.

The substrate may take the form of a matrix.

The substrate may take the form of a plastic or other synthetic surface in the form of a sheet, tube or mesh, onto which the collagen is directly deposited forming a collagenous coating.

The substrate may also take the form of a composite, for example, various synthetic layers bonded to an artificially or naturally-produced matrix.

These collagen coated substrates may also be chemically modified. For example, glutaraldehyde or similar chemicals may be used to stabilise the matrix.

The collagen of the present invention may be used as a paste or slurry. Such a paste or slurry would have a number of applications including as an implant material such as in the form of an injectable medium for use in cosmetic surgery. Such a slurry may be stabilized chemically such as by glutaraldehyde or irradiation. Such as with gamma radiation. The concentration of this tactoidal collagen in the paste or slurry is preferably not less than 10 mgm/ml, more preferably not less than 30 mgm/ml and most preferably not less than 40 mgm/ml.

The collagen useful for forming the collagen products of this invention includes collagen derived from hides, skins or other collagen containing organs or tissues of humans or other vertebrates or invertebrates and includes collagens of one type or mixtures of types. Soluble collagen can be prepared by enzymic treatment of collagen from those sources. Suitable enzymes include pepsin.

The collagen may also be derived from the culture medium of cells, tissues or organs grown in cell- or tissue-culture. The culture medium used to produce the collagen may be a culture medium from cell or tissue culture derived from a person for whom a synthetic body part is

to be produced; it is believed that doing this will substantially reduce the likelihood of rejection. Further, it is also possible that a substrate may be introduced into the culture medium such that collagen and other components will be directly produced thereon. Such a substrate may have the form of a particular body part or biomedical product desired. The substrate may take the form of a matrix. The substrate may take the form of a plastic or other synthetic surface in the form of a sheet, tube or mesh, onto which the collagen and other components are directly deposited forming a collagenous coating. The substrate may be formed from aggregates of tactoidal collagen of this invention.

The water soluble or miscible polymer is preferably a neutral polymer. Such polymers may be at least one of the synthetic polymers polyvinyl alcohol, polyethylene oxide, polyvinylpyrrolidinone, polyacrylamide, polyethylene glycol, polypropylene glycol, polyvinyl methyl ether, maleic anhydride copolymers and the like; or at least one of the modified, natural, neutral polymers hydroxyethyl starches, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose or the like; or at least one of the natural neutral polymers agarose, dextrins, dextrans, starches, pectins, alginates and the like. Mixtures of such polymers may be used and the molecular weight of the polymer or polymers can vary over a wide range provided the polymer remains soluble or miscible with water.

This list of polymers is not exhaustive as the important factor is the use of a water soluble polymer or polymers to precipitate the collagen. Neutral water soluble or miscible polymers are preferable but charged, water soluble polymers may also be used particularly if they are only mildly charged.

The precipitate of collagen is generally found to be improved if it is allowed to stand in said solution. Such standing is preferable for a period of one hour to six months with one day to one month being more preferred.

Such standing is effected at temperatures between the denaturation temperature of the collagen and the freezing point of the solution; preferably at between zero and 20°C; more preferably between zero and 10°C.

If desired, added materials such as plasticisers, colourants, biologically active materials such as proteoglycans or glycosaminoglycans, proteins, other extracellular products, hormones, growth factors, antibiotics and agents which affect wound healing or have other beneficial effects, ionic strength modifiers such as salts, or solids such as insoluble collagen or the like may be included with the so precipitated collagen and incorporated into material made from the collagen. These added materials may also be incorporated into the solution of soluble collagen before addition of the polymer or otherwise incorporated into material made from the collagen. Charged, water soluble or water miscible polymers may be used as part of a mixture with the neutral polymer or polymers and added to the soluble collagen with the neutral polymer solution. These charged polymers may be used to modify the properties of the soluble collagen solution or the material made from the precipitated collagen.

The collagen product of this invention may be chemically or biochemically stabilised. Biochemical stabilisation may be effected by enzymes such as lysyl oxidase. Chemical stabilisation may be effected by tanning agents, syntans, other cross-linking agents or chemical modifiers of collagen. Of particular interest are stabilisers which limit proteolysis or the immunogenicity of the collagen. Glutaraldehyde is a stabiliser of particular interest. The product may also be stabilised by dehydration by mild heat, water miscible solvents, critical point drying or the like. Such stabilisation may be performed before or after a shaping operation. The collagen product of this invention may be sterilised chemically or by irradiation.

Chemical sterilisation may be conducted by means of suitable solutions of sterilising materials such as glutaraldehyde from between 0.5% to 5% concentration. The product may be stored in solutions of sterilant until required for use. Sterilisation by means of irradiation can be conducted by exposing the collagen product of this invention to gamma rays from a suitable source. From 0.5 to 5 Mrads of irradiation may be used, preferably 2.5 Mrads of gamma ray irradiation is suitable for satisfactory sterilisation of the product.

The tactoids formed by precipitation of the soluble collagen in this invention are useful in production of synthetic body parts, and other materials for medical or veterinary applications. The collagen tactoids or tactoid assemblages could be stabilised by chemical or biochemical techniques or could be formed into various useful shapes and then stabilised. The tactoidal collagen has potential application in many areas such as the manufacture of collagen sponges or haemostatic agents , of dressings, of membranes, of skin, of tubes and the like and in the treatment of disease such as peridontal disease. The tactoidal collagen can also be used in conjuction with other structural type materials to form composite materials with different properties. For example, a tube of tactoidal collagen can be covered with a woven or knitted mesh of fibre such as Dacron to give the tube additional strength. Alternatively, the tactoidal collagen can be formed into a tube surrounding the mesh to give a more intimate contact with the mesh and better properties. To better utilise the properties of the tactoidal collagen in the formation of artificial body parts it is possible to arrange the tactoids in a preferred orientation by the application of an electric field or by means of mechanical action. Materials made from the oriented tactoids may have beneficial effects in the healing of wounds. Many other methods of utilising the tactoidal collagen in a variety of shapes and forms

and in conjuction with diverse other materials can be envisaged.

The product of this invention also has application in areas outside medical and veterinary products including plastics, fabric, leather or as composites or the like.

The present invention also includes such collagen products and articles produced therefrom.

The collagen products of this invention have advantages over presently available products. These include, low immunogenicity, ease of preparation, high collagen content, and strength.

The following examples illustrate the invention.

EXAMPLE 1

Type I collagen was solubilised and extracted from foetal calfskin by pepsin digestion and purified by fractional salt precipitation according to the method of Trelstad et al.(1967). This purified collagen was dissolved in 200 mM Tris-HCl buffer pH 7.5 at 4°C and at a concentration of 10 mg/ml. Polyethylene glycol (PEG) 4000 was than added to produce a final concentration of 2.5% (w/v). A precipitate of tactoidal collagen formed which settled to the bottom of the container after standing at 4°C for a few hours or could be concentrated by filtration or centrifugation.

EXAMPLE 2

As for Example 1 except that the concentration of the collagen was 1 mg/ml.

EXAMPLE 3

As for Example 2 except that PEG 400 to a final concentration of 3.5% (w/v) was used to precipitate the collagen.

EXAMPLE 4

Type III collagen, solubilised and extracted as in Example 1, was dissolved at a concentration of 1 mg/ml in 200mM Tris- HCl buffer pH7.6 at 4°C. PEG 400 was added to the solution to a final concentration of 4.0% (w/v) and the precipitate of tactoidal collagen formed.

EXAMPLE 5

As for Example 4 except that a final concentration of 2.5% (w/v) PEG 4000 was used.

EXAMPLE 6

Type II collagen was isolated by the method of Trelstad et al. (1976) from bovine articular cartilage by pepsin solubilisation and fractional salt precipitation. The purified type II collagen was dissolved in 200 mM Tris- HCl buffer at pH 7.6 at 4°C and at a concentration of 1 mg/ml. PEG 400 was then added to produce a final concentration of 3.0% (w/v). The precipitate of tactoidal collagen formed as in Examples above.

EXAMPLE 7

As for Example 6 except that PEG 4000 was added to a final concentration of 2.0% (w/v).

EXAMPLE 8

As for Example 1 except that PEG 1000 to a final concentration of 5% (w/v) was used to precipitate the collagen.

EXAMPLE 9

As for Example 1 except that PEG 10000 to a final concentration of 5% (w/v) was used to precipitate the collagen.

EXAMPLE 10

The suspension of tactoidal collagen from Example 1 was stored at 4°C for 4 weeks and collected on Whatman No. 1 filter paper in a 125 mm diameter basket centrifuge rotating at 4000 rpm. The resulting collagen sheet was removed from the centrifuge and separated from the filter paper. The collagen sheet was found to have properties similar to those of a thick, wet paper tissue and to be suitable for assisting in the healing of open skin wounds.

EXAMPLE 11

The collagen sheet, prepared as in Example 10, was tanned using a solution of 0.01% glutaraldehyde for 18 hours. After drying the sheet was found to have a

tensile strength of 6.2N/sq cm and an elongation of 12% at a moisture content of 16%.

EXAMPLE 12

The collagen sheet, prepared as in Example 10 was sealed in a polyethylene bag and subjected to 2.5Mrads of gamma ray irradiation. The sheet was found to have been sterilised and to have improved tensile properties over those of the sheet in Example 10.

EXAMPLE 13

As for Example 2 except that the buffer was at pH5.

EXAMPLE 14

As for Example 1 except that the collagen extracted from foetal calfskin was not purified by fraction salt precipitation but was used as a crude extract and that 5% PEG 4000 was used.

EXAMPLE 15

As for Example 14 except that 5% polyvinyl alcohol was used.

EXAMPLE 16

As for Example 14 except that 5% dextran of 10,000 average molecular weight was used.

EXAMPLE 17

As for Example 14 except that 5% dextran of 40,000 average molecular weight was used.

EXAMPLE 18

A collagen sheet prepared as in Example 10 was rolled into a tube and then stabilized by tanning using a solution of 0.01% glutaraldehyde for 18 hours.

EXAMPLE 19

A collagen sheet prepared as in Example 10 was dried by critical point drying using liquid carbon dioxide.

BIBLIOGRAPHY

Chvapil, M. (1979) - In "Fibrous Proteins, Scientific, Industrial and Medical Aspects", Vol. 1 (Eds Parry, D.A.D. and Creamer L.K.) Academic Press, London pp 247-269. Bornstein, P. and Traub, W. (1979) In "The Proteins" Vol 4 (Eds Neurath, H. and Hill, R.L.) Academic Press, New York pp411-632.

Linsenmeyer, T.F. (1982) In "Collagen in Health and Disease" (Eds Weiss, J.B. and Jayson, M.I.V.) Churchill Livingston, Edinburgh pp244-268.

Leibovich. S.J. and Weiss, J.B. (1970) Biochim. Biophys. Acta 214:445-465. Electron microscope studies of the effects of endo- and exo-peptidase digestion on tropocollagen.

Lee, S.L. and Piez, K.A. (1983) Collagen Rel. Res. 3:98-103. Type II collagen from Lathyritic rat chondrosarcoma: preparation and in vitro fibril formation.

Trelstad, R.L., Catanese, V.M. and Rubin, D.F. (1976) Anal. Biochem. 71:114-118. Collagen fractionation: Separation of native types I, II and III by differential precipitation.

Modifications and adaptations may be made to the above described without departing from the spirit and scope of this invention which includes every novel feature and combination of features disclosed herein.

CLAIMS:

1. Collagen in tactoid form obtained by forming an aqueous solution containing dissolved collagen and a water soluble or miscible polymer adapted to precipitate collagen out of solution in the form of tactoids.

2. A method of producing a collagen product comprising forming an aqueous solution containing dissolved collagen and a water soluble or miscible polymer adapted to precipitate the collagen out of solution in the form of tactoids.

3. A method of producing a collagen product as claimed in claim 2, wherein the pH of said solution is 3.5 - 10.

4. A method of producing a collagen product as claimed in claim 2, wherein the pH of said solution is 7 - 8.

5. A method of producing a collagen product as claimed in any one of claims 2 - 4, including forming the thus formed precipitate to a shape.

6. A method of producing a collagen product as claimed in any one of claims 2 - 5, including precipitating the collagen onto a pre-shaped substrate.

7. A method of producing a collagen product as claimed in claim 6, wherein the substrate has the form of a body part.

8. A method of producing a collagen product as claimed in claim 6, wherein the substrate is itself formed of collagen in the form of tactoids.

9. A method of producing a collagen product as claimed in claim 5, wherein prior to forming said precipitate to a shape the precipitate is permitted to stand in said solution for a period of greater than 1 hour.

10. A method of producing a collagen product as claimed in claim 9, wherein the temperature of standing is from 0 - 20°C.

11. A method of producing a collagen product as claimed in any one of claims 2 - 10, and including the step of chemically or biochemically stabilizing the collagen so formed.

12. A method of producing a collagen product as claimed in any one of claims 2 - 11, wherein the dissolved collagen is

derived from cell or tissue culturing.

13. A method of producing a collagen product as claimed in any one of claims 2 - 12, wherein said water soluble or miscible polymer is selected from polyvinyl alcohol, polyethylene oxide, polyvinylpyrrolidinone, polyacrylamide, polyethylene glycol, polypropylene glycol, polyvinyl methyl ether, maleic anhydride copolymers and the like.

14. A method of producing a collagen product as claimed in any one of claims 2 - 12, wherein said water soluble or miscible polymer is selected from hydroxyethyl starches, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose or the like.

15. A method of producing a collagen product as claimed in any one of claims 2 - 12, wherein said water soluble or miscible polymer is selected from agarose, dextrins, dextrans, starches, pectins, alginates and the like.

16. Collagen as claimed in claim 1 and in admixture with a biologically active material.

17. Collagen as claimed in claim 1 and in the form of a synthetic body part.

18. Collagen as claimed in claim 1 and precipitated onto a shaped substrate.

19. Collagen as claimed in claim 17 and in the form of a sheet or tube.

20. Collagen as claimed in claim 1 and in the form of a slurry or paste.

21. Collagen as claimed in claim 20 and containing at least 10 mgm/ml of collagen.

22. A method of producing a collagen product substantially as hereinbefore described with reference to any one of the Examples.

23. Collagen in tactoid form substantially as hereinbefore described with reference to any one of the Examples.

24. The articles, things, parts, elements, steps, features, methods, processes, compounds and compositions referred to or indicated in the specification and/or claims of the application individually or collectively, and any and all combinations of any two or more of such.

INTERNATIONAL SEARCH REPORT

International Application No PCT/AU 87/00038

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) [6]

According to International Patent Classification (IPC) or to both National Classification and IPC

Int. Cl.[4] A61L 27/00; C07K 15/12, 15/20; C08J 3/14; C08L 89/00, 89/06

II. FIELDS SEARCHED

Minimum Documentation Searched [7]

Classification System	Classification Symbols
IPC	A61L 27/00; C07K 15/12, 15/20; C08J 3/14; C08L 89/00, 89/06

Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched [8]

AU : IPC as above, Australian Classification 47.72

III. DOCUMENTS CONSIDERED TO BE RELEVANT [9]

Category *	Citation of Document, [11] with indication, where appropriate, of the relevant passages [12]	Relevant to Claim No. [13]
A	AU,A, 33803/84 (JOHNSON AND JOHNSON) 18 April 1985 (18.04.85)	
A	AU,A, 47013/85 (COLLAGEN CORPORATION) 13 March 1986 (13.03.86)	
A	AU,A, 51602/85 (COLLAGEN CORPORATION) 17 July 1986 (17.07.86)	
A	US,A, 4585797 (CIOCA) 29 April 1986 (29.04.86)	
A	US,A, 4407787 (STEMBERGER) 4 October 1986 (04.10.86)	
A	US,A, 4264155 (MIYATA) 28 April 1981 (28.04.81)	

* Special categories of cited documents: [10]

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report
10 April 1987 (10.04.87)	(05.05.87) 5 MAY 1987
International Searching Authority	**Signature of Authorized Officer**
Australian Patent Office	L. MENZ

Form PCT/ISA/210 (second sheet) (January 1985)

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON
INTERNATIONAL APPLICATION NO. PCT/AU 87/00038

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report	Patent Family Members		
AU 33803/84	EP 140596 US 4614794	GB 8326542 ZA 8407780	GB 2148901
AU 47013/85	EP 174175	JP 61137826	US 4557764
AU 51602/85	EP 187014	JP 61210040	US 4600533
US 4585797	AR 230006 FR 2503561	BR 8200482 US 4591501	DE 3204512 ZA 8108919
US 4407787	CA 1167726 HK 534/86	DE 3037513 JP 58041559	EP 49469
US 4264155	JP 56011430	US 4268131	

END OF ANNEX